The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Explosive Growth Trajectory

• Extended-release drugs market size surged from $57.11 billion in 2023 to $63.82 billion in 2024.
• Compound Annual Growth Rate (CAGR) of 11.7% was witnessed.
• Historic period growth attributed to:
  • Improvement in patient compliance.
  • Prevalence of chronic diseases.
  • Enhanced efficacy of medications.
  • Patent protection strategies.
  • Biodegradable implants.
• Anticipated growth to $99.77 billion in 2028 at a CAGR of 11.8%.
• Forecast period growth factors:
  • Personalized medicine approaches.
  • Patient-centric drug development.
  • Rising lifestyle diseases.
  • Drug repurposing.
  • Global access to extended-release therapies.

Read More On The Extended-Release Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market

• Chronic conditions incidence escalates, driving market growth.
• Extended-release systems ensure steady medication levels.
• Examples of chronic conditions: heart disease, cancer, obesity, diabetes.
• By 2050, individuals aged 50+ with at least one chronic illness may surge by 99.5%.
• Major companies shaping the market:
  • Pfizer Inc.
  • AbbVie Inc.
  • Novartis AG.
  • Sanofi SA.
  • GlaxoSmithKline PLC.
  • And others.

Pioneer In Epilepsy Treatment Innovation

• Product innovation gains traction.
• Companies launch innovative products to maintain market standing.
• Example: Zydus Pharmaceuticals’ Topiramate extended-release capsules for epilepsy.
• Pfizer’s strategic acquisition of Arena Pharmaceuticals for $6.7 billion in March 2022.
• Arena Pharmaceuticals’ promising extended-release medications in cardiology, dermatology, and gastroenterology.

Segmentation and Geographic Trends

• Market segmented by type (sustained release, controlled release) and mode (OTC, prescription).
• Distribution channels include hospital pharmacies, retail pharmacies, mail order pharmacies, drug stores.
• North America led the market in 2023.
• Asia-Pacific projected as the fastest-growing region.

Pharmaceutical Innovation Shaping the Future

• Major trends in the forecast period:
  • Pharmaceutical innovation.
  • Advancements in drug delivery systems.
  • Progress in nanotechnology.
  • Utilization of 3D printing in drug formulations.
  • Integration of artificial intelligence.
  • Emphasis on environmental sustainability.

The extended-release drug market is a dynamic landscape, driven by innovation and a response to the evolving healthcare needs of a growing population. With an increasing prevalence of chronic conditions and a demand for more effective and convenient treatment options, the market is poised for significant expansion in the coming years. As companies continue to invest in research and development and explore new technologies, the potential for breakthroughs in drug delivery and patient care remains high.

Request for A Sample Of The Global Extended-Release Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=12675&type=smp